NO833465L - 1,2,3,4-tetrahydro-1-aminometyl-4-fenylisokinoliner og fremgangsmaate ved fremstilling derav - Google Patents
1,2,3,4-tetrahydro-1-aminometyl-4-fenylisokinoliner og fremgangsmaate ved fremstilling deravInfo
- Publication number
- NO833465L NO833465L NO833465A NO833465A NO833465L NO 833465 L NO833465 L NO 833465L NO 833465 A NO833465 A NO 833465A NO 833465 A NO833465 A NO 833465A NO 833465 L NO833465 L NO 833465L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- hydrogen
- tetrahydro
- phenylisoquinoline
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 4
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 4
- QJOVNULYKFBKGT-UHFFFAOYSA-N (4-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methanamine Chemical class C12=CC=CC=C2C(CN)NCC1C1=CC=CC=C1 QJOVNULYKFBKGT-UHFFFAOYSA-N 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 7
- -1 1- (substituted methylene)-3,4-dihydro-4-phenylisoquinolines Chemical class 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960000582 mepyramine Drugs 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- KAWBUIDBMPROCA-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylisoquinoline Chemical compound C12=CC=CC=C2C(CCl)=NC=C1C1=CC=CC=C1 KAWBUIDBMPROCA-UHFFFAOYSA-N 0.000 description 3
- NYFWTNQFJQJPTR-UHFFFAOYSA-N 2-chloro-n-(2-hydroxy-1,2-diphenylethyl)acetamide Chemical compound C=1C=CC=CC=1C(O)C(NC(=O)CCl)C1=CC=CC=C1 NYFWTNQFJQJPTR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XQCHKDVNXJXGGS-UHFFFAOYSA-N n-methyl-1-(4-phenylisoquinolin-1-yl)methanamine;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(CNC)=NC=C1C1=CC=CC=C1 XQCHKDVNXJXGGS-UHFFFAOYSA-N 0.000 description 3
- ABSPXUAYPUJLBV-SZKOKKDDSA-N n-methyl-1-[(1r,4s)-4-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1([C@@H]2CN[C@H](C3=CC=CC=C32)CNC)=CC=CC=C1 ABSPXUAYPUJLBV-SZKOKKDDSA-N 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BISZUZSNQOOGOJ-UHFFFAOYSA-N 1-(chloromethyl)-4-phenyl-3,4-dihydroisoquinoline Chemical compound C12=CC=CC=C2C(CCl)=NCC1C1=CC=CC=C1 BISZUZSNQOOGOJ-UHFFFAOYSA-N 0.000 description 2
- GWUZTCVSWZSNGC-UHFFFAOYSA-N 1-[(dimethylamino)methyl]-4-phenyl-3,4-dihydro-1h-isoquinoline-2-carbaldehyde Chemical compound C12=CC=CC=C2C(CN(C)C)N(C=O)CC1C1=CC=CC=C1 GWUZTCVSWZSNGC-UHFFFAOYSA-N 0.000 description 2
- GEJJWYZZKKKSEV-UHFFFAOYSA-N 2-amino-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(N)C(O)C1=CC=CC=C1 GEJJWYZZKKKSEV-UHFFFAOYSA-N 0.000 description 2
- 238000006407 Bischler-Napieralski reaction Methods 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- LRZDVHGXRNOTTB-UHFFFAOYSA-N n,n-dimethyl-1-(4-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C(CN(C)C)NCC1C1=CC=CC=C1 LRZDVHGXRNOTTB-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- WAKHLWOJMHVUJC-FYWRMAATSA-N (2e)-2-hydroxyimino-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(=N/O)\C(O)C1=CC=CC=C1 WAKHLWOJMHVUJC-FYWRMAATSA-N 0.000 description 1
- JKNSFSHEVNOOHK-UHFFFAOYSA-N (4-phenyl-3,4-dihydroisoquinolin-1-yl)methanamine Chemical compound C12=CC=CC=C2C(CN)=NCC1C1=CC=CC=C1 JKNSFSHEVNOOHK-UHFFFAOYSA-N 0.000 description 1
- DSJUYVRAFKJQER-UHFFFAOYSA-N 1-(chloromethyl)-4-phenyl-3,4-dihydroisoquinoline;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(CCl)=NCC1C1=CC=CC=C1 DSJUYVRAFKJQER-UHFFFAOYSA-N 0.000 description 1
- OXSDPKKYPZJMAR-UHFFFAOYSA-N 2-chloro-n-(1,1-diphenylethyl)acetamide Chemical compound C=1C=CC=CC=1C(NC(=O)CCl)(C)C1=CC=CC=C1 OXSDPKKYPZJMAR-UHFFFAOYSA-N 0.000 description 1
- UVBXCNDFSWKPKY-UHFFFAOYSA-N 2-chloro-n-(2,2-diphenylethyl)acetamide Chemical compound C=1C=CC=CC=1C(CNC(=O)CCl)C1=CC=CC=C1 UVBXCNDFSWKPKY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000003326 anti-histaminergic effect Effects 0.000 description 1
- WAKHLWOJMHVUJC-UHFFFAOYSA-N benzoin alpha-oxime Natural products C=1C=CC=CC=1C(=NO)C(O)C1=CC=CC=C1 WAKHLWOJMHVUJC-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- CHMTVTQSVZOKGI-UHFFFAOYSA-N n,n-dimethyl-1-(2-methyl-4-phenyl-3,4-dihydro-1h-isoquinolin-1-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C(CN(C)C)N(C)CC1C1=CC=CC=C1 CHMTVTQSVZOKGI-UHFFFAOYSA-N 0.000 description 1
- KEUSBNOLUMCSQJ-UHFFFAOYSA-N n,n-dimethyl-1-(4-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methanamine Chemical compound C12=CC=CC=C2C(CN(C)C)NCC1C1=CC=CC=C1 KEUSBNOLUMCSQJ-UHFFFAOYSA-N 0.000 description 1
- RCSHHPYOJZSUOW-UHFFFAOYSA-N n-[(4-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]ethanamine;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C(CNCC)NCC1C1=CC=CC=C1 RCSHHPYOJZSUOW-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/423,958 US4518779A (en) | 1982-09-27 | 1982-09-27 | 1,2,3,4-Tetrahydro-1-aminomethyl-4-phenyl isoquinolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO833465L true NO833465L (no) | 1984-03-28 |
Family
ID=23680888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO833465A NO833465L (no) | 1982-09-27 | 1983-09-26 | 1,2,3,4-tetrahydro-1-aminometyl-4-fenylisokinoliner og fremgangsmaate ved fremstilling derav |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4518779A (de) |
| EP (1) | EP0104604B1 (de) |
| JP (1) | JPS5978164A (de) |
| KR (1) | KR840006209A (de) |
| AT (1) | ATE34386T1 (de) |
| AU (1) | AU564040B2 (de) |
| BR (1) | BR8305272A (de) |
| CA (1) | CA1228360A (de) |
| DE (1) | DE3376650D1 (de) |
| DK (1) | DK438883A (de) |
| FI (1) | FI833443A (de) |
| IE (1) | IE55970B1 (de) |
| IL (1) | IL69624A (de) |
| NO (1) | NO833465L (de) |
| NZ (1) | NZ205422A (de) |
| PH (1) | PH19712A (de) |
| ZA (1) | ZA836330B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330360B1 (de) * | 1988-02-19 | 1993-12-01 | SmithKline Beecham Farmaceutici S.p.A. | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten |
| GB8827479D0 (en) * | 1988-11-24 | 1988-12-29 | Zambeletti Spa L | Novel compounds |
| MX2019000980A (es) * | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3420818A (en) * | 1964-08-07 | 1969-01-07 | Sandoz Ag | Tetrahydroisoquinolines |
| US3435038A (en) * | 1965-06-01 | 1969-03-25 | Sandoz Ag | 5,6,7,9,10,14b-hexahydroisoquinolo (2,1-d) benzo (1,4) diazepines |
| US3666763A (en) * | 1970-01-06 | 1972-05-30 | Hoffmann La Roche | 4-phenyl isoquinolines and process for preparing same |
| DK496275A (da) * | 1974-11-06 | 1976-05-07 | Fujisawa Pharmaceutical Co | Fremgangsmade til fremstilling af 1,2,3,4-tetrahydroisoquinoliner |
| DE2811361A1 (de) * | 1978-03-16 | 1979-09-27 | Hoechst Ag | Neue isochinolinaldehyde und verfahren zu ihrer herstellung |
| JPS5587771A (en) * | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
| DE3011156A1 (de) * | 1980-03-22 | 1981-10-01 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur herstellung von isochinolinderivaten |
| US4340600A (en) * | 1980-05-22 | 1982-07-20 | Smithkline Corporation | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines |
-
1982
- 1982-09-27 US US06/423,958 patent/US4518779A/en not_active Expired - Fee Related
-
1983
- 1983-08-23 CA CA000435199A patent/CA1228360A/en not_active Expired
- 1983-08-26 ZA ZA836330A patent/ZA836330B/xx unknown
- 1983-08-26 PH PH29451A patent/PH19712A/en unknown
- 1983-08-30 NZ NZ205422A patent/NZ205422A/en unknown
- 1983-09-01 IL IL69624A patent/IL69624A/xx unknown
- 1983-09-14 AU AU19112/83A patent/AU564040B2/en not_active Ceased
- 1983-09-20 IE IE2205/83A patent/IE55970B1/xx unknown
- 1983-09-21 EP EP83109410A patent/EP0104604B1/de not_active Expired
- 1983-09-21 DE DE8383109410T patent/DE3376650D1/de not_active Expired
- 1983-09-21 AT AT83109410T patent/ATE34386T1/de not_active IP Right Cessation
- 1983-09-22 JP JP58174447A patent/JPS5978164A/ja active Pending
- 1983-09-26 DK DK438883A patent/DK438883A/da not_active Application Discontinuation
- 1983-09-26 FI FI833443A patent/FI833443A/fi not_active Application Discontinuation
- 1983-09-26 NO NO833465A patent/NO833465L/no unknown
- 1983-09-26 BR BR8305272A patent/BR8305272A/pt unknown
- 1983-09-26 KR KR1019830004494A patent/KR840006209A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4518779A (en) | 1985-05-21 |
| DK438883D0 (da) | 1983-09-26 |
| KR840006209A (ko) | 1984-11-22 |
| ZA836330B (en) | 1984-07-25 |
| AU564040B2 (en) | 1987-07-30 |
| JPS5978164A (ja) | 1984-05-04 |
| IE55970B1 (en) | 1991-03-13 |
| IE832205L (en) | 1984-03-27 |
| EP0104604B1 (de) | 1988-05-18 |
| DK438883A (da) | 1984-03-28 |
| BR8305272A (pt) | 1984-05-02 |
| NZ205422A (en) | 1986-07-11 |
| IL69624A0 (en) | 1983-12-30 |
| ATE34386T1 (de) | 1988-06-15 |
| AU1911283A (en) | 1984-04-05 |
| IL69624A (en) | 1987-01-30 |
| FI833443A0 (fi) | 1983-09-26 |
| EP0104604A1 (de) | 1984-04-04 |
| CA1228360A (en) | 1987-10-20 |
| FI833443A (fi) | 1984-03-28 |
| PH19712A (en) | 1986-06-17 |
| DE3376650D1 (en) | 1988-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0286263B1 (de) | Psychotropische polycyclische Imide | |
| US4649198A (en) | Imidazo(1,5-a)pyrimidine derivatives and their use as antimycotic agents | |
| GB1569039A (en) | Derivatives of 10,11-dihydrobenzo(4,5)-cyclohepta(1,2-b)-pyrazolo(4,3-e)-pyridine-5(1h)one | |
| HU196377B (en) | Process for production of 2-substituated-amin-5-acethilimidasoles | |
| NO833465L (no) | 1,2,3,4-tetrahydro-1-aminometyl-4-fenylisokinoliner og fremgangsmaate ved fremstilling derav | |
| CZ291218B6 (cs) | 1-[2-(Substituovaný vinyl)]-5H-2,3-benzodiazepinové deriváty, způsob jejich výroby, farmaceutické přípravky je obsahující a jejich pouľití | |
| US4220771A (en) | 2,3-Polymethylene-4-oxo-4H-pyrido[1,2-a]pyrimidines | |
| NO833778L (no) | 1,3,4,6,7,11b-heksahydro-7-aryl-2h-pyrazino(2,1-alfa)isokinoliner og fremgangsmaate ved fremstilling derav | |
| FI79533C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-substituerade isokinolinderivat. | |
| US4251659A (en) | Polyfluorohydroxyisopropyl-heterocyclic compounds | |
| US4167638A (en) | Process for production of 8-NHR quinolines | |
| HU192836B (en) | Process for producing substituted azabicyclo-alkane derivatives and pharmaceutical compositions containing them | |
| GB2081261A (en) | Condensed as-triazine derivatives and process for preparing the same | |
| US3966723A (en) | 1,2,3,4,10,14B-Hexahydro-pyridino[1,2-a]-dibenzo[c,f]-azepine | |
| Clark et al. | Antihypertensive 9-substituted 1-0xa-4, 9-diazaspiro [5.5] undecan-3-ones | |
| CA1133483A (en) | Hexahydro-trans-pyridoindole neuroleptic agents | |
| EP0202950B1 (de) | Berbanderivate und ihre Herstellung und pharmazeutische Zubereitung | |
| NZ201292A (en) | 2-substituted-cycloalka(f)benzo(b)(oxa(thia)zoles or 1,3-diazoles) | |
| US4014885A (en) | Anti-leukemic oxygenated benzo[c]phenanthridine compounds | |
| EP0153994B1 (de) | [Bis(substituiertes methyl)-methyl]isochinolinderivate, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, die sie enthalten | |
| US4056529A (en) | Dibenzopyrimidoazepines | |
| US3998842A (en) | Diazepino[1,2-α]indoles | |
| NZ205031A (en) | Trans 1-substituted-3-optionally substituted-6-oxo-7-formyldecahydroquinoline derivatives | |
| MURAKAMI et al. | Studies on Morphinan Derivatives. I. The Synthesis of Several New 3-Substituted Derivatives of N-Methylmorphinan having Antitussive Activities | |
| US3991059A (en) | 2-Methyl-3-phenyl-2,3,7,8,9,9α-hexahydro-1H-benz[de] quinoline |